After announcing it would start selling its assets earlier this year, along with laying off nearly half the company, the medical app developer Akili Interactive has found a willing buyer.

The US Food and Drug Administration (FDA) has approved Onyda XR (clonidine hydrochloride) for the treatment of attention-deficit/hyperactivity disorder (ADHD), drug manufacturer Tris Pharma announced in a statement. The drug is the first approved liquid nonstimulant ADHD medication. The once-daily extended-release oral suspension, with nighttime dosing, can be used alone or as an adjunctive therapy…

Parents and other grownups are currently being diagnosed with the disorder at the same rate as children. Why now?

Adults in the United States are seeking assessment, diagnosis, and treatment for attention-deficit/hyperactivity disorder (ADHD) at unprecedented rates. Psych Congress Network sat down with Lenard A. Adler, MD, director of the Adult ADHD Program at NYU Langone Health, on site at the 2024 APA Annual Meeting to dive deep into the particular ways that ADHD…

A study of university students in Lebanon found that 35.7% of those suffering from gaming disorder also suffer from attention-deficit/hyperactivity disorder (ADHD). This percentage was 24% among those without gaming disorder. Interestingly, the association between ADHD and gaming disorder was stronger in females than in males. The research was published in the journal PLOS ONE.

Virtual gaming has redefined what constitutes “playtime” for many children and adolescents, but no consensus has yet been reached on how helpful or harmful that trend may be, especially for youth living with attention-deficit/hyperactivity disorder (ADHD). A literature review presented via poster at the 2024 American Psychiatric Association Annual Meeting in New York City, though,…

Cingulate Inc has announced alignment with the US Food and Drug Administration (FDA) on the requirements for filing a New Drug Application (NDA) for its lead candidate, CTx-1301 (dexmethylphenidate). This medication is intended for the treatment of attention-deficit /hyperactivity disorder (ADHD) in patients aged 6 years and older.1

Adolescents with unmedicated attention-deficit/hyperactivity disorder (ADHD) who meet sleep guidelines have a lower risk for overweight and obesity (OW/OB) than those with short sleep duration, according to study findings published in the Journal of Pediatric Psychology.

Students with disabilities face a gamut of challenges when it comes to accessing high-quality K-12 education, including a shortage of specialized teachers. The nation’s growing English-learner population faces outsized needs as their English-language proficiency scores remain lower than pre-COVID-19-pandemic averages, and immigrant English learners in particular require more trauma-informed instruction.

Neonatal hypoglycemia is associated with an increased risk for suboptimal neurodevelopmental outcomes in mid-childhood, according to study findings published in JAMA Network Open.

Cambridge scientists have shown that problems regulating emotions—which can manifest as depression, anxiety and explosive outbursts—may be a core symptom of attention deficit hyperactivity disorder (ADHD). In research published in Nature Mental Health, the team found that as many as one in two children with ADHD show signs of emotional dysregulation, and that Ritalin—the commonly-prescribed…

Adult patients receiving treatment for attention-deficit/hyperactivity disorder (ADHD) for the first time have an increased 10-year risk for stroke, heart failure, and a composite cardiovascular outcome, with a higher risk occurring with a higher dosage, according to a study in the Journal of the American College of Cardiology.